Colistin Monotherapy versus Colistin plus Sitafloxacin for Therapy of Carbapenem-Resistant Infections: A Preliminary Study.

The in vitro study of sitafloxacin against carbapenem-resistant (CR) demonstrated activity against most strains of CR , and the combination of colistin and sitafloxacin showed an in vitro synergistic effect against CR . This study aimed to compare efficacy and safety between colistin plus sitafloxacin with colistin alone for therapy for CR infection. This randomized controlled trial enrolled 56 patients with CR infection (28/group) during 2018-2021, and the treatment duration was 7-14 days.